Floatz logo

68ga-hbed-ipsma

Metastatic Prostate Cancer

Memorial Sloan Kettering Cancer CenterradiopharmaceuticalActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

59 Active assets in the Metastatic Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Sipuleucel-T
Yale University
Phase 2BB
Degarelix
Praful Ravi, MB BCHir, MRCP
Phase 3BB
PIFLUFOLASTAT
Brigham and Women's Hospital
Phase 4BB
Apalutamide
AstraZeneca
Phase 4BB

View all 50 →

Same molecule, other indications

68ga-hbed-ipsma is also rated in:

prostate adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
46 / 100
View asset →
metastatic prostate carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →